AMAG Pharmaceuticals (NASDAQ:AMAG) will release its earnings data before the market opens on Thursday, November 1st. Analysts expect AMAG Pharmaceuticals to post earnings of ($0.67) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.54). The firm had revenue of $146.25 million during the quarter, compared to the consensus estimate of $156.26 million. AMAG Pharmaceuticals had a negative net margin of 36.87% and a negative return on equity of 2.77%. The business’s revenue for the quarter was up 12.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.40) earnings per share. On average, analysts expect AMAG Pharmaceuticals to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of AMAG Pharmaceuticals stock traded up $0.16 during trading on Tuesday, reaching $21.56. The stock had a trading volume of 4,761 shares, compared to its average volume of 639,840. The firm has a market cap of $757.37 million, a price-to-earnings ratio of -3.74 and a beta of 0.56. AMAG Pharmaceuticals has a 52 week low of $11.93 and a 52 week high of $26.10. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.06 and a quick ratio of 1.95.
In related news, CEO William K. Heiden sold 5,000 shares of the company’s stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the chief executive officer now owns 328,015 shares in the company, valued at $8,200,375. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.00% of the company’s stock.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Read More: How to Invest in an Index Fund
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.